The carcinoGENOMICS project: critical selection of model compounds for the development of omics-based in vitro carcinogenicity screening assays.

M. Vinken*, T. Doktorova, H. Ellinger Ziegelbauer, H.J. Ahr, E. Lock, P. Carmichael, E. Roggen, J. van Delft, J. Kleinjans, J. Castell, R. Bort, T. Donato, M. Ryan, R. Corvi, H. Keun, T. Ebbels, T. Athersuch, S.A. Sansone, P. Rocca Serra, R. StierumP. Jennings, W. Pfaller, H. Gmuender, T. Vanhaecke, V. Rogiers

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review


    Recent changes in the European legislation of chemical-related substances have forced the scientific community to speed up the search for alternative methods that could partly or fully replace animal experimentation. The Sixth Framework Program project carcinoGENOMICS was specifically raised to develop omics-based in vitro screens for testing the carcinogenic potential of chemical compounds in a pan-European context. This paper provides an in-depth analysis of the complexity of choosing suitable reference compounds used for creating and fine-tuning the in vitro carcinogenicity assays. First, a number of solid criteria for the selection of the model compounds are defined. Secondly, the strategy followed, including resources consulted, is described and the selected compounds are briefly illustrated. Finally, limitations and problems encountered during the selection procedure are discussed. Since selecting an appropriate set of chemicals is a frequent impediment in the early stages of similar research projects, the information provided in this paper might be extremely valuable
    Original languageEnglish
    Pages (from-to)202-210
    JournalMutation Research-Reviews in Mutation Research
    Issue number3
    Publication statusPublished - 1 Jan 2008

    Cite this